Drug Trial Radar · NCT05869643
A Clinical Trial of STP0404 in Adults With HIV-1 Infection
Last checked: Nov 20, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
May 23, 2023
Primary completion
Apr 25, 2026
Study completion May 6, 2026
Sponsor
- Lead sponsor
- ST Pharm Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the antiviral effect, safety, tolerability, and pharmacokinetics of STP0404 in adult participants living with Human Immunodeficiency Virus Type 1 (HIV-1) infection.
Conditions
- HIV-1-infection
Interventions
Low-dose STP0404 (Pirmitegravir)Drug
Once daily, oral capsule taken after breakfast
Medium-dose STP0404 (Pirmitegravir)Drug
Once daily, oral capsule taken after breakfast
High-dose STP0404 (Pirmitegravir)Drug
Once daily, oral capsule taken after breakfast
PlaceboDrug
Matching placebo capsule, taken orally once daily after breakfast
Primary outcomes
What the sponsor says the trial is designed to measure.
- HIV-1 RNA copies change in plasmaTime frame: Day 1, Day 11
- Total Number of Adverse Events (AEs) occurring through Day 11Time frame: Through day 11
- Total Number of Serious Adverse Events (SAEs) occurring through Day 11Time frame: Through day 11
- Mean area under the concentration-time curve from zero to 24 hours (AUC0-24h)Time frame: Day 1, Day 10
- Mean observed maximum concentration after administration (Cmax)Time frame: Day 1, Day 10
- Mean time to reach Cmax (Tmax)Time frame: Day 1, Day 10
- Mean observed concentration at 24 hours after administration (C24h)Time frame: Day 2, Day 4, Day 7, Day10, Day 11
- Mean area under the concentration-time curve to infinite time (AUCinf)Time frame: Day 10
- Mean area under the concentration-time curve to time t (AUCt)Time frame: Day 10
- Mean terminal half-life (t1/2)Time frame: Day 10
- Mean apparent oral clearance (CL/F)Time frame: Day 10
- Mean apparent volume of distribution (Vd/F)Time frame: Day 10
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Kaiser Permenente Los Angeles Medical Center
Los Angeles, California
Ruane Clinical Research, Inc.
Los Angeles, California
Midway Immunology and Research Center
Ft. Pierce, Florida
Schiff Center for Liver Diseases/University of Miami
Miami, Florida
Orlando Immunology Center
Orlando, Florida
USF Health South Tampa Center for Advanced Healthcare
Tampa, Florida
Be Well Medical Center
Berkley, Michigan
Saint Michael's Medical Center
Newark, New Jersey
South Jersey Infectious Disease
Somers Point, New Jersey
North Shore University Hospital
Manhasset, New York
Atrium Health Wake Forest Baptist Medical Center - PPDS
Winston-Salem, North Carolina
St Hope Foundation, Inc
Bellaire, Texas
North Texas Infectious Diseases Consultants, P.A.
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.